Search - tctmd.com

Displaying 81 - 100 of 174

Sort: Relevancy | Date

Presentation TCT 2016

From APTITUDE to MAGNITUDE: Progress Towards the Development of a Thin-walled Novel PLLA-based Polymeric BRS

Presenter: Ron Waksman, Robert-Jan van Geuns, Juan F. Granada

October 31, 2016

Presentation TCT 2016

FIRESORB PLLA-Based Sirolimus-Eluting Scaffold: 6-Month FUTURE-I Results

Presenter: Ron Waksman, Robert-Jan van Geuns, Bo Xu

October 31, 2016

Presentation TCT 2016

MIRAGE: Design Novelty and 1-Year Results With a Microfiber-Based BRS

Presenter: Ron Waksman, Robert-Jan van Geuns, Patrick W. Serruys

October 31, 2016

Presentation TCT 2016

AMS/Dreams Evolution to Magmaris: Latest Outcomes With Magnesium-Based Stents

Presenter: Ron Waksman, Robert-Jan van Geuns, Michael Haude

October 31, 2016

Presentation TCT 2016

MeRes100 Design Specifications and the 6-months MeRes-1 Results

Presenter: Ron Waksman, Robert-Jan van Geuns, Ashok Seth

October 31, 2016

Presentation TCT 2016

FANTOM: Novel Design Attributes and 6-Month FANTOM II Results

Presenter: Ron Waksman, Robert-Jan van Geuns, Jose de Ribamar Costa Jr

October 31, 2016

Presentation TCT 2016

Desolve Nx, Cx and Amity: Unique Properties and Results From 150 Um To 120 Um

Presenter: Ron Waksman, Robert-Jan van Geuns, Alexandre Abizaid

October 31, 2016

Presentation TCT 2016

Outcome Registries III: 2-Year Results From ASSURE

Presenter: Stephen G. Ellis, Corrado Tamburino, Detlef G. Mathey

October 31, 2016

Presentation TCT 2016

ABSORB III Critique: Pros and Cons

Presenter: Sunil V. Rao, Harvey D. White, Ron Waksman

October 31, 2016

Presentation TCT 2016

Trial #1 - The Essentials of ... ABSORB III Everolimus-Eluting Bioresorbable Vascular Scaffolds vs Everolimus-Eluting Metallic Stents in Coronary Artery Disease

Presenter: Sunil V. Rao, Harvey D. White, Stephen G. Ellis

October 31, 2016

News Conference News TCT 2016

‘Worrisome’ 3-Year Data From ABSORB II Raise Concerns About First-Generation Bioresorbable Stent

Michael O'Riordan

October 30, 2016

News Opinion Editor's Corner TCT 2016

TCT 2016: Inspiration and Perspiration Greet Left Main Stenting, Hoop Dreams, Valve Innovation, and Election Fever

Shelley Wood

October 24, 2016

News Features

The Bioresorbable Stent Story So Far: What Promise? What Price?

Michael O'Riordan

August 17, 2016

News Daily News

Absorb BVS 的 18 个月结果“令人安心”，但仍需要更长期的随访

Michael O'Riordan

August 01, 2016

News Daily News

“Tranquilizadores” Resultados a 18 Meses con el AVB Absorb Aunque Todavía Necesitamos Seguimientos Más Largos

Michael O'Riordan

August 01, 2016

News Daily News

‘Reassuring’ 18-Month Results Seen With Absorb BVS, but Longer-Term Follow-up Still Needed

Michael O'Riordan

August 01, 2016

News Daily News

Now You See It: FDA Approves Absorb Bioresorbable Scaffold

Michael O'Riordan

July 05, 2016

News Daily News

Prolonged Full-Dose Bivalirudin May Preserve Bleeding Benefit Without Upping Thrombotic Events After STEMI, Meta-Analysis Suggests

Yael L. Maxwell

June 20, 2016

News Daily News

Survey of Interventional Cardiologists With Absorb BVS Expertise Gives Snapshot of Attitudes, Usage

Michael O'Riordan

June 14, 2016

News Conference News EuroPCR 2016

Reassuring Registry Data Suggest Scaffold Thrombosis Rates with BVS Declining

Michael O'Riordan

May 17, 2016

Advertisement

From APTITUDE to MAGNITUDE: Progress Towards the Development of a Thin-walled Novel PLLA-based Polymeric BRS

FIRESORB PLLA-Based Sirolimus-Eluting Scaffold: 6-Month FUTURE-I Results

MIRAGE: Design Novelty and 1-Year Results With a Microfiber-Based BRS

AMS/Dreams Evolution to Magmaris: Latest Outcomes With Magnesium-Based Stents

MeRes100 Design Specifications and the 6-months MeRes-1 Results

FANTOM: Novel Design Attributes and 6-Month FANTOM II Results

Desolve Nx, Cx and Amity: Unique Properties and Results From 150 Um To 120 Um

Outcome Registries III: 2-Year Results From ASSURE

ABSORB III Critique: Pros and Cons

Trial #1 - The Essentials of ... ABSORB III Everolimus-Eluting Bioresorbable Vascular Scaffolds vs Everolimus-Eluting Metallic Stents in Coronary Artery Disease

‘Worrisome’ 3-Year Data From ABSORB II Raise Concerns About First-Generation Bioresorbable Stent

TCT 2016: Inspiration and Perspiration Greet Left Main Stenting, Hoop Dreams, Valve Innovation, and Election Fever

The Bioresorbable Stent Story So Far: What Promise? What Price?

Absorb BVS 的 18 个月结果“令人安心”，但仍需要更长期的随访

“Tranquilizadores” Resultados a 18 Meses con el AVB Absorb Aunque Todavía Necesitamos Seguimientos Más Largos

‘Reassuring’ 18-Month Results Seen With Absorb BVS, but Longer-Term Follow-up Still Needed

Now You See It: FDA Approves Absorb Bioresorbable Scaffold

Prolonged Full-Dose Bivalirudin May Preserve Bleeding Benefit Without Upping Thrombotic Events After STEMI, Meta-Analysis Suggests

Survey of Interventional Cardiologists With Absorb BVS Expertise Gives Snapshot of Attitudes, Usage

Reassuring Registry Data Suggest Scaffold Thrombosis Rates with BVS Declining

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content